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Introduction {#sec1}
============

The clinical spectrum of coronavirus disease 2019 (COVID-19) associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) varies from asymptomatic disease to severe pneumonia and death \[[@bib1],[@bib2]\]. Increased serum concentrations of inflammatory and coagulation markers (including C-reactive protein (CRP), ferritin, and D-dimer) and proinflammatory cytokines (such as IL-2R, IL-6, IL-10, and TNF-α) have been associated with disease severity in COVID-19 \[[@bib3],[@bib4]\]. These findings indicate that a hyperinflammatory state may play a crucial role in severe cases of COVID-19, as in other coronaviruses \[[@bib5]\].

Regarding treatment of COVID-19, so far remdesivir is the only antiviral that has shown some efficacy \[[@bib6]\]. Because of the dysregulated immune response characteristic of severe COVID-19, it is conceivable that immunosuppressant drugs may have some effect in selected patients. Despite the fact that some guidelines have recommended against the use of corticosteroids \[[@bib7],[@bib8]\], dexamethasone (6 mg/day) in the RECOVERY trial reduced mortality among those receiving either invasive mechanical ventilation or oxygen alone \[[@bib9]\]. Other host response modifiers under investigation include tocilizumab, a recombinant humanized anti-human IL-6 receptor \[[@bib10]\], for which some comparative observational studies have been reported \[[@bib11], [@bib12], [@bib13], [@bib14]\].

Observational studies may help in the design of randomized trials of immunomodulatory agents for the treatment of severe COVID-19 by providing an estimation of their potential effects and identifying potential candidates for these therapies. The objective of this study was to provide an observational estimation of the association between tocilizumab/corticosteroids and outcome in non-intubated patients, specifically in those with data suggestive of a hyperinflammatory state, within a large nationwide clinical cohort of patients with COVID-19 to test the hypothesis that these drugs might be associated with a reduced risk of intubation or death.

Methods {#sec2}
=======

Design, patients and procedures {#sec2.1}
-------------------------------

The SAM-COVID study is a retrospective cohort study nested in the COVID19\@Spain cohort (NCT04355871), in which consecutive patients admitted to Spanish hospitals because of COVID-19 (confirmed by PCR in nasopharyngeal swab or lower respiratory tract sample) from February 2nd to March 31st 2020 were included \[[@bib15]\]. SAM-COVID was also registered (NCT04382781) before the analysis started.

Adult patients from the COVID19\@Spain cohort were eligible for SAM-COVID if presenting on a specific date (day 0) with at least one clinical criterion and one laboratory criterion suggestive of a hyperinflammatory state. Clinical criteria were (a) temperature ≥38°C and (b) increase in oxygen support required to achieve O~2~ saturation \>92%. Laboratory criteria were (a) ferritin \>2000 ng/mL or increase \>1000 ng/mL since admission, (b) D-dimers \>1500 μg/mL (or doubled in 24 h), and (c) IL6 \>50 pg/mL. Investigators from the COVID\@Spain cohort sites were asked to further review the charts of patients by assessing daily clinical and laboratory data, and to provide additional information. Exclusion criteria were (a) being under mechanical ventilation at day 0, (b) occurrence of the primary endpoint in ≤2 day after day 0 (in order to avoid immortal time bias), (c) written decision to avoid any escalation in medical treatment before day 0, (d) previous use of systemic corticosteroids, tocilizumab, other immunomodulatory drugs or immunoglobulins, and (e) treatment with immunomodulatory drugs other than corticosteroids or tocilizumab, or with immunoglobulins during the first 48 h after day 0. In addition, day 0 must have been before March 31 to assure 21 days of follow-up when the database was locked. Sixty hospitals participated in this study. The database was monitored for missing data and inconsistencies.

Variables {#sec2.2}
---------

The main endpoint was intubation or death, whichever happened first; follow-up was 21 days. Patients were censored on the last day of contact if discharged before day 21. Secondary outcomes were death, rates of secondary bacterial infection, digestive tract bleeding, and proportion of patients with a score of ≤3 in a seven-point ordinal scale at day 21 (1, not hospitalized; 2, hospitalized without supplemental oxygen; 3, hospitalized with supplemental oxygen; 4, hospitalized and requiring supplemental oxygen with a high nasal flow cannula or non-invasive ventilation; 5, hospitalized and requiring mechanical ventilation; 6, hospitalized and requiring extracorporeal membrane oxygenation (ECMO) or invasive mechanical ventilation with amine support; and 7, death).

The main treatments after day 0 were with tocilizumab, intermediate-high dose corticosteroids (IHDC), pulse dose corticosteroids (PDC), combination therapy with tocilizumab and corticosteroids, or no treatment. In order to try to mimic the exposure as in a randomized trial and intention-to-treat analysis, we classified exposure to treatment arms in the primary analysis as follows: patients were assigned to tocilizumab, IHDC or PDC if administered in ≤2 days after day 0; patients receiving both tocilizumab and corticosteroids in the first 2 days were assigned to the combination treatment group, while patients not receiving any of these drugs were assigned to the non-treatment arm. Patients who started treatment with the above drugs in days 3 and 4 were excluded from the primary analysis, as it would be debatable to which arm they should be assigned, and to avoid immortal time bias; however, these patients were included in a sensitivity analysis in which treatments were considered as time-dependent variables. Corticosteroid treatment was classified as PDC if ≥ 250 mg of methylprednisolone or equivalent per day were administered, or as IHDC otherwise. Other variables collected are included in [Table 1](#tbl1){ref-type="table"} . The data were obtained from the patients\' charts. An electronic case report was built using REDCap electronic data capture tools \[[@bib16]\]. Missing values were classified as a separate category in the analyses.Table 1Demographic and clinical data of patients. Data are number (proportion) of patients with known exposure to the variable except where specifiedTable 1No treatment (*n* = 344)Tocilizumab (*n* = 88)p value[a](#tbl1fna){ref-type="table-fn"}Corticosteroids, intermediate--high dose (*n* = 117)p value[b](#tbl1fnb){ref-type="table-fn"}Corticosteroids, pulse dose (*n* = 78)p value[c](#tbl1fnc){ref-type="table-fn"}Combination therapy (*n* = 151)P value[d](#tbl1fnd){ref-type="table-fn"}Age, median years (IQR)69 (59--76)66 (56--72)0.1071 (62--76)0.0571 (60--76)0.2465 (58--74)0.01Female gender106/343 (30.9)24/64 (27.3)0.5033/116 (28.4)0.6121/78 (26.9)0.4842/149 (28.1)0.54Caucasian ethnicity316/338 (93.5)80/87 (92.0)0.61110/113 (97.3)0.1275/78 (96.2)0.37132/147 (89.8)0.15**Comorbidities:**Cardiac disease62/344 (18.0)11/88 (12.5)0.2121/117 (17.9)0.9811/78 (14.1)0.4017/150 (11.3)0.06Hypertension175/344 (50.9)30/88 (34.1)0.00561/117 (52.1)0.8142/78 (53.8)0.6373/151 (48.3)0.60Chronic pulmonary disease37 (10.8)6/88 (6.8)0.2718/117 (15.4)0.189/78 (11.5)0.8417/151 (11.3)0.86Severe chronic renal insufficiency13 (3.8)0/87 (0)0.083/116 (2.6)0.775/78 (6.4)0.341/151 (0.7)0.07Liver cirrhosis5/337 (1.5)1/87 (1.1)1.01/117 (0.9)1.01/78 (1.3)1.00/151 (0)0.33Malignancy15/344 (4.4)1/88 (1.1)0.094/117 (3.4)0.394/78 (5.1)0.892/151 (1.3)0.07HIV infection0/344 (0)1/88 (1.1)0.200/117 (0)---0/78 (0)---0/151 (0)---Obesity39/309 (11.4)12/78 (14.3)0.5419/111 (17.1)0.165/68 (7.4)0.2223/134 (17.2)0.20Diabetes mellitus72/344 (20.9)15/88 (17.0)0.4129/117 (24.8)0.3812/78 (15.4)0.2626/151 (17.2)0.34Dementia14/344 (4.1)1/88 (1.1)0.184/117 (2.4)0.7500.080/151 (0)0.01**Admission data:**Percentage oxygen saturation with room air, mean (SD)92.6 (6.0)92.1 (6.4)0.5191.0 (5.1)0.190.0 (5.6)0.00191.8 (5.2)0.19Bilateral infiltrates in thorax radiography235/288 (81.6)67/78 (85.9)0.3791/102 (89.2)0.0752/69 (82.6)0.84132/131 (87.0)0.16Lymphocytes/μL, mean (SD)1069 (1049)989 (814)0.671313 (1952)0.091244 (1753)0.25948 (520)0.17LDH in U/L, mean (SD)388 (158)392 (143)0.39388 (152)0.20385 (119)0.39408 (166)0.73C-reactive protein in mg/L, mean (SD)112 (101)118 (100)0.64124 (107)0.28118 (99)0.63112 (99)0.96**Antiviral treatment before day 0:**Lopinavir/ritonavir242/335 (72.2)71/87 (81.6)0.0786/117 (73.5)0.7959/78 (75.6)0.49111/151 (73.5)0.77Hydroxychloroquine319/335 (94.4)86/88 (97.7)0.27104/117 (88.9)0.0473/78 (93.6)0.84144/151 (95.4)0.65Remdesivir3/334 (0.9)0/88 (0)1.00/117 (0)0.520/78 (0)1.00/151 (0)0.55Azithromycin223/337 (66.2)65/88 (73.9)0.1679/117 (67.5)0.7948/78 (61.5)0.58116/147 (78.9)0.005Interferon β71/332 (21.4)24/86 (27.9)0.1925/116 (21.6)0.9712/78 (15.4)0.8427/151 (17.9)0.85**Data on day 0:**Median days of symptoms (IQR)8 (6--11)10 (8--13)0.0210 (7--12)0.056 (9--12)0.2211 (8--13)\<0.001Median days from admission to day 0 (IQR)1 (0--4)3 (1--5)0.0012 (1--4)0.082 (1--5)0.213 (1--5)0.001Fever202/344 (58.7)42/88 (47.7)0.0665/117 (55.6)0.5438/78 (48.7)0.1077/151 (51.0)0.11Worsening in oxygen requirements230/344 (66.9)81/88 (92.0)\<0.00187/117 (74.4)0.1370/78 (89.7)\<0.001136/151 (90.1)\<0.001Ferritin \>2000 ng/mL95/194 (49.0)19/59 (32.2)0.0234/78 (43.6)0.4229/62 (46.8)0.7651/100 (51.0)0.74D-dimers \>1500 μg/mL192/311 (61.7)43/82 (52.4)0.1255/112 (49.1)0.0240/73 (54.8)0.2778/140 (55.7)0.24IL6 \>50 pg/mL100/132 (75.8)57/59 (96.6)\<0.00147/53 (88.7)0.0426/37 (70.3)0.4981/95 (85.3)0.07**Oxygen support at day --1:**0.0010.0010.001\<0.001 Nasal cannula or mask282/340 (82.9)57/88 (63.6)82/117 (70.1)51/78 (65.3)71/149 (48.3) Mask with reservoir bag46/340 (13.5)26/88 (29.2)30/117 (25.6)25/78 (32.1)65/149 (43.0) High-flow nasal cannula10/340 (2.9)3/88 (3.4)1/117 (0.9)1/78 (1.3)5/149 (3.3) Non-invasive mechanical ventilation2/340 (0.6)2/88 (3.4)4/117 (3.4)1/78 (1.3)8/149 (5.3)**Low-molecular-weight heparin:** Prophylactic dose244/340 (71.8)69/88 (80.2)0.2293/117 (79.5)0.1157/78 (73.1)0.88115/150 (76.7)0.27 Anticoagulant dose36/340 (10.6)12/88 (14.0)0.4417/117 (14.5)0.2316/78 (20.5)0.0126/150 (17.3)0.03**Immunomodulatory drugs after day 4:**Corticosteroids, low dose39/344 (11.3)11/88 (12.5)0.71------35/78 (44.9)\<0.001------Corticosteroids, high dose26/344 (7.5)6/88 (6.8)1.00/117 (0)\<0.001------------Tocilizumab22/344 (6.5)------7/117 (5.9)0.8710/78 (12.8)0.08------[^2][^3][^4][^5][^6]

The study was approved by the University hospitals Virgen Macarena and Virgen del Rocío ethic committee which waived the need to obtain written informed consent due to the observational nature of the study. The study is reported according to STROBE recommendations ([Supplementary Material Table S1](#appsec1){ref-type="sec"}).

Statistical analysis {#sec2.3}
--------------------

Patients classified as receiving no treatment were compared to those treated with tocilizumab, IHDC, PDC, or combination treatment for baseline variables at admission and day 0 using Student t-test or Mann--Whitney U test for continuous variables and χ^2^ or Fisher test for categorical variables, as appropriate. The association of treatment with time-related endpoints was analysed using Kaplan--Meier curves and Cox regression analysis. The sites were included as a random effect variable in the models. Propensity scores for receiving early treatment with tocilizumab, IHDC, PDC or combination therapy instead of no treatment were calculated by performing non-parsimonious multivariate logistic regression models by including all measured potential predictors for treatment. The ability of the propensity scores to predict the observed data was calculated by the area under the receiver operating characteristic curve (AUROC) with 95% confidence intervals (95%CIs). The propensity scores were used to calculate the inverse probability of treatment weight (IPTW) in Cox analysis, as a confounder and as a matching variable (treated/not treated, 1:2 ratio), using the nearest neighbour method with a tolerance \<5%. When the proportional hazards assumptions were not fulfilled for performing Cox regression, logistic regression (conditional if matched analyses) was used. Multivariate models with forward addition of different variables to the model adjusted by the propensity score were also performed, after excluding collinearity. Sensitivity analyses were performed by including patients who started treatments on days 3 and 4, and considering exposure to study drugs as time-dependent variables, counting the days until the first dose of the drug was administered from day 0. All analyses were performed using IBM SPSS Statistics v26 and R.

Results {#sec3}
=======

Overall, 1014 eligible patients were identified; 778 were included in the primary analysis ([Fig. 1](#fig1){ref-type="fig"} ), including 344 in the no-treatment arm, 88 treated with tocilizumab, 117 with IHDC, 78 with PDC, and 151 with combination treatment (all received tocilizumab, 77 received IHDC and 74 PDC).Fig. 1Flowchart of patients included in the primary analysis.Fig. 1

The features of the patients are shown in [Table 1](#tbl1){ref-type="table"}. Overall, patients in the treatment arms needed a higher level of oxygen support at day 0 than those in the no-treatment arm. The proportion of patients with measured and elevated levels of IL-6 was higher in the tocilizumab and IHDC arms; it was the only laboratory criterion for inclusion in 24.4% of the patients. By contrast, ferritin and D-dimers were less frequently elevated in the tocilizumab and IHDC arms, respectively. Details regarding the drugs dosing are shown in the [Supplementary Material Table S2](#appsec1){ref-type="sec"}.

The crude outcomes of patients according to treatment arm are shown in [Table 2](#tbl2){ref-type="table"} , and crude Kaplan--Meier curves for the primary endpoint are shown in [Fig. 2](#fig2){ref-type="fig"} . The proportional hazard assumption was not fulfilled in the comparison of IHDC and combination versus no treatment, and logistic regression was used for these comparisons. The propensity score-adjusted associations of treatments for the primary endpoint are shown in [Table 3](#tbl3){ref-type="table"} , which also includes the variables used for the propensity score calculation. The comparison of features of the propensity score-matched patients are shown in the [Supplementary Material Table S3](#appsec1){ref-type="sec"}. The IPTW-adjusted Kaplan--Meier curves for tocilizumab and PDC are shown in the [Supplementary Material Fig. S1](#appsec1){ref-type="sec"}. Overall, tocilizumab was associated with lower hazard for the primary endpoint in all adjusted analyses; the estimations for PDC were all on the protective side but were significant only in the IPTW model. IHDC and combination therapy were not associated with significant risk differences. Addition of other variables to the models and sensitivity analyses considering treatments as time-dependent variables provided no significant changes in the estimations.Table 2Crude outcomes of patients in the different treatment arms. Data are number (proportion) of patients with known exposure to the variable except where specifiedTable 2No treatment (*n* = 344)Tocilizumab (*n* = 88)p value[a](#tbl2fna){ref-type="table-fn"}Corticosteroids, intermediate--high dose (*n* = 117)p value[b](#tbl2fnb){ref-type="table-fn"}Corticosteroids, pulse dose (*n* = 78)p value[c](#tbl2fnc){ref-type="table-fn"}Combination (*n* = 151)p value[d](#tbl2fnd){ref-type="table-fn"}Primary outcome[e](#tbl2fne){ref-type="table-fn"}69/344 (20.1)10/88 (11.4)0.0527/117 (23.1)0.5712/78 (15.4)0.2840/151 (26.5)0.13Median follow-up without the endpoint, days (IQR)20 (13--21)21 (16--21)0.0121 (16--21)0.5621 (12.21)0.5520 (11--21)0.87Scale at day 21*n* = 344*n* = 88---*n* = 117---*n* = 78---*n* = 151--- 1253 (73.5)70 (79.5)80 (68.4)55 (70.5)100 (66.2) 210 (2.9)2 (2.3)4 (3.4)2 (2.6)8 (5.3) 316 (4.7)8 (9.1)8 (6.8)8 (10.3)14 (9.3) 44 (1.2)001 (1.3)1 (0.7) 519 (5.5)6 (6.8)2 (1.7)4 (5.1)9 (6.0) 61 (0.3)01 (0.9)019 (6.0) 7 (death)41 (11.9)2 (2.3)0.00422 (18.8)0.088 (10.3)0.8419 (12.6)0.88 Scale ≤3279 (81.1)80 (90.9)0.0292 (78.6)0.5665 (83.3)0.64122 (80.8)0.93Digestive tract bleeding2/341 (0.6)1/88 (1.1)0.491/115 (1.4)1.01/74 (1.4)0.443/150 (2.0)0.16Secondary bacterial infection36/339 (10.3)11/88 (12.5)0.5710/115 (8.7)0.728/75 (10.7)1.018/150 (12.0)0.64[^7][^8][^9][^10][^11][^12]Fig. 2Probability of remaining event-free (intubation or death) according to the different treatments used, in comparison with no treatment (crude analyses). (A) Tocilizumab. (B) Corticosteroids, intermediate-high dose. (C) Corticosteroids, pulse dose. (D) Combination therapy.Fig. 2Table 3Estimation of the association of treatments with the primary endpoint (time until intubation or death) and with mortality in the different models. Adjusted models used specific propensity scores[a](#tbl3fna){ref-type="table-fn"} for receiving each drugTable 3**Intubation or deathTocilizumab versus no treatmentHR (95%CI)p**Crude0.52 (0.27--1.01)0.05With propensity score0.32 (0.15--0.67)0.003Inverse probability of treatment weights0.32 (0.22--0.47)\<0.001Matched cases0.42 (0.19--0.92)0.03Time-dependent variable with propensity score0.36 (0.17--0.75)0.007**Corticosteroids, intermediate-high dose versus no treatmentOR (95%CI)p**Crude1.17 (0.71--1.95)0.52With propensity score0.83 (0.48--1.45)0.53Inverse probability of treatment weights1.00 (0.72--1.41)0.96Matched cases0.80 (0.42--1.41)0.50Time-dependent variable with propensity score0.95 (0.59--1.53)0.84**Corticosteroids, pulse dose versus no treatmentHR (95%CI)p**Crude0.71 (0.38--1.32)0.28With propensity score0.71 (0.36--1.38)0.31Inverse probability of treatment weights0.61 (0.43--0.86)0.006Matched cases0.69 (0.32--1.51)0.36Time-dependent variable with propensity score0.79 (0.41--1.53)0.50**Combination therapy versus no treatmentOR (95%CI)p**Crude1.41 (0.90--2.21)0.13With propensity score1.20 (0.71--2.01)0.48Inverse probability of treatment weights1.17 (0.86--1.58)0.30Matched cases1.71 (0.88--3.31)0.10Time-dependent variable with propensity score1.17 (0.74--1.84)0.48**DEATHTocilizumab versus no treatmentHR (95%CI)p**Crude0.17 (0.04--0.70)0.01With propensity score0.12 (0.02--0.56)0.007Inverse probability of treatment weights0.07 (0.02--0.17)\<0.001Matched cases0.22 (0.05--0.96)0.04**Corticosteroids, intermediate-high dose versus no treatmentHR (95%CI)p**Crude1.66 (0.99--2.79)0.05With propensity score1.16 (0.66--2.03)0.59Inverse probability of treatment weights1.21 (0.62--2.35)0.56Matched cases1.02 (0.66--1.58)0.90**Corticosteroids, pulse dose versus no treatmentOR (95%CI)p**Crude0.80 (0.35--1.81)0.59With propensity score0.74 (0.31--1.77)0.51Inverse probability of treatment weights0.64 (0.24--1.04)0.06Matched cases0.67 (0.24--1.84)0.43**Combination therapy versus no treatmentOR (95%CI)p**Crude1.03 (0.57--1.85)0.90With propensity score1.31 (0.67--2.54)0.42Inverse probability of treatment weights1.17 (0.75--1.64)0.57Matched cases1.36 (0.58--3.21)0.47[^13]

Regarding the secondary outcomes, the crude estimations are shown in [Table 2](#tbl2){ref-type="table"}. The proportion of patients with a score ≤3 on the 7-point scale at day 21 was higher in the tocilizumab arm. No differences were seen in the rates of secondary bacterial infection or gastrointestinal bleeding. Regarding mortality, the Kaplan--Meier curves (crude data) are shown in the [Supplementary Material Fig. S2](#appsec1){ref-type="sec"}. The adjusted analyses are shown in [Table 3](#tbl3){ref-type="table"}, and the IPTW-adjusted Kaplan--Meier curves are in the [Supplementary Material Fig. S3](#appsec1){ref-type="sec"}. Tocilizumab was associated with a lower hazard of death in all adjusted models. PDC was nearly associated with a lower risk of death only in the IPTW model; neither IHDC nor combination therapy could demonstrate a significant association with mortality ([Table 3](#tbl3){ref-type="table"}).

Discussion {#sec4}
==========

In this observational, multicentre, propensity score-adjusted study, tocilizumab was associated with lower hazards of intubation or death in patients with COVID-19 presenting with clinical and laboratory data suggestive of a hyperinflammatory state. The association with PDC was also significant in the analysis with the IPWT but not with other adjustments, although the estimations are informative. On the other hand, we could not find a significant association between IHDC or combination therapy and outcomes.

One of the problems in observational studies is the assignment of patients to treatment arms. In this study we mimicked exposure and intention-to-treat analysis in randomized trials, in which treatments are typically started in ≤2 days, and we excluded patients for whom the endpoint was reached in such a period or patients starting treatment in days 3 and 4, in order to avoid immortal time bias. In fact, sensitivity analysis which included patients treated on days 3--4 and considered exposure to drugs as time-dependent variables did not show different results, suggesting that immortal time bias was not affecting the estimations.

We used a 'hard' composite primary outcome including intubation or death because some patients may be candidates for additional medical treatment but not for intubation due to their previous conditions. Anyhow, the results were similar when only mortality or the proportions of patients with a score of ≥3 in the 7-point scale were considered. Our data were not specific for adverse events, and this is a crucial aspect that should be considered in more detail in future studies.

Regarding confounders, we used propensity scores in different ways in order to control for the indication bias. Because the IPTW provides a higher weight to patients treated with the drug of interest when having a lower probability of receiving that drug, the confidence intervals are reduced, while in the case of tocilizumab all models showed a significant association with improved outcomes; it was only with this analysis that PDC showed a significant association. We hypothesize that the lack of significant association with other analysis for PDC might be due to insufficient statistical power.

We found four observational comparative studies with tocilizumab in non-intubated patients with severe COVID-19 pneumonia. In one of them, 32 patients treated with tocilizumab were compared to 33 controls; patients treated with tocilizumab showed numerically lower mortality but the differences were not significant \[[@bib11]\]. In another, treatment with tocilizumab (62 patients) was associated with better adjusted survival and a favourable clinical course in comparison with standard treatment (23 patients) \[[@bib12]\]. A third study compared 179 patients treated with tocilizumab (88 intravenously) with 365 receiving standard of care in three Italian centres; tocilizumab was associated with a lower adjusted risk of invasive mechanical ventilation or death \[[@bib13]\]. Finally, a fourth study found lower mortality in non-intubated patients, but adjusted analyses were not performed \[[@bib14]\]. Several randomized trials with tocilizumab are ongoing; a press release by the promoter of the COVACTA trial reported that it did not show superiority over placebo in the primary endpoint (data not published) \[[@bib17]\]. However, inclusion criteria in this trial did not consider data suggestive of a hyperinflammatory state \[[@bib18]\].

Regarding corticosteroids, recent meta-analyses showed contradictory results \[[@bib19],[@bib20]\]. In these reviews, the dosing of corticosteroids was not specified. The results from a quasi-experimental study suggested that early administration of 0.5--1 mg/kg of methylprednisolone for 3 days is associated with a protective effect for a composite outcome including admission to ICU, mechanical ventilation or death \[[@bib21]\], while a cohort study including 35 propensity score-matched couples of patients with and without corticosteroids (methylprednisolone, 40--50 mg/day) found no significant differences in outcomes \[[@bib22]\]. A preliminary report of data from the RECOVERY randomized trial found that dexamethasone 6 mg/day (equivalent to methylprednisolone 30 mg) resulted in lower mortality among patients requiring oxygen or mechanical ventilation; the effect was more prominent in patients under mechanical ventilation \[[@bib9]\]. It should be noted that corticosteroids in our study were used at higher doses in most patients, and were started only once the patients had developed a hyperinflammatory state based on clinical and laboratory data. We found no studies with pulse dose corticosteroids. While our results in this group are less clear, we think they support the development of a randomized trial in this clinical situation. We did not find any studies investigating the combination of tocilizumab and corticosteroids; the negative results in our study should be taken with caution since this was a heterogeneous group including different timing and dosing of both drugs. We could not perform more detailed analysis in this group since the numbers of patients in the subgroups were too low.

This study has several limitations. First, control for confounders in any observational study may be incomplete despite all efforts. Second, even though we registered the study design before performing any analysis, the criteria for assignment to study arms were not specified; however, they were decided before the analyses were performed. Third, a wide range of dosing regimens were used in the corticosteroid arms. Fourth, the investigators were not blinded for the exposure; however, we used hard outcomes and included consecutive cases. Fifth, the assessment of adverse events was not complete. And sixth, the study was performed during the first month of the pandemic in Spain; management may have changed afterwards.

The study also has some strengths, including the multicentre participation, the use of specific exposure definitions and advanced analyses for observational studies, and representativeness of real-life patients.

In conclusion, these findings suggest that testing tocilizumab should be prioritized for being tested in randomized trials targeting patients with data suggestive of a hyperinflammatory state, and that pending further evidence, it should be considered with caution in the treatment of this condition if participation in randomized trials is not possible. Additional data are needed for tocilizumab in patients who previously received corticosteroids, which might be the standard of care now. The results for PDC were less consistent but are also encouraging.
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The following are the Supplementary data to this article:Multimedia component 1Multimedia component 1 Multimedia component 2Multimedia component 2

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.cmi.2020.08.010>.

[^1]: The members of the SAM-COVID Study Group are mentioned in the [Appendix](#appsec1){ref-type="sec"} section.

[^2]: IQR: interquartile range.

[^3]: For tocilizumab versus no treatment.

[^4]: For corticosteroids, high-intermediate dose versus no treatment.

[^5]: For corticosteroids, pulse dose versus no treatment.

[^6]: For combination versus no treatment.

[^7]: IQR, interquartile range.

[^8]: For tocilizumab versus no treatment.

[^9]: For corticosteroids, intermediate-high dose versus no treatment.

[^10]: For corticosteroids, pulse dose versus no treatment.

[^11]: For combination versus no treatment.

[^12]: P values obtained by univariate Cox regression except for combination therapy, for which logistic-regression was used.

[^13]: Propensity scores were calculated including age, gender, ethnicity, comorbidities (cardiac disease, hypertension, chronic pulmonary disease, chronic renal disease, liver cirrhosis, malignancy, diabetes mellitus, obesity, HIV infection), laboratory data (lymphocytes, lactate dehydrogenase, alanine aminotransferase, ferritin, D-dimers, IL-6), previous treatments, radiographic findings, 7-point scale and type of oxygen requirement. Their predictive ability for observed data are 0.79 (95%CI: 0.74--0.85) for tocilizumab, 0.72 (0.68--0.77) for corticosteroids, intermediate-high dose, 0.77 (0.71--0.82) for corticosteroids, pulse dose, and 0.81 (0.77--0.85) for combination therapy.
